Management Comment "The MAA for abaloparatide-SC is based on the results from the ACTIVE and ACTIVExtend trials, which demonstrated significant clinical benefit for postmenopausal women at risk of osteoporotic fracture," said Robert Ward, President and CEO of Radius Health. "The acceptance of our application for review by the EMA represents a significant step towards potentially bringing abaloparatide-SC to postmenopausal women with osteoporosis in Europe, and Radius looks forward to working with the EMA in the review procedure."